Punish the parent not the progeny.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Blood

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2004-08-3373PMID 15528314
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• Mechanisms controlling pathogenesis and survival of leukemic stem cells

  2004cited by this paper
• BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

  2004cited by this paper
• Characterization of acute lymphoblastic leukemia progenitor cells.

  2004cited by this paper
• Active transport of imatinib into and out of cells: implications for drug resistance.

  2004cited by this paper
• Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

  2004cited by this paper
• Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

  2004cited by this paper
• Getting at the root and stem of brain tumors.

  2004cited by this paper
• Imatinib mesylate ( STI 571 ) is a substrate for the breast cancer resistance protein ( BCRP ) / ABCG 2 drug pump

  2004cited by this paper
• Imatinib Mesylate Does Not Inhibit BCR-ABL Kinase Activity in CML Stem Cells In Vitro.

  2004cited by this paper
• Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

  2004cited by this paper
• The BCR-ABL story: bench to bedside and back.

  2004cited by this paper
• Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

  2004cited by this paper
• Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors.

  2003cited by this paper
• Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

  2003cited by this paper
• The Farnesyl Protein Transferase Inhibitor Lonafarnib (SCH66336) Is an Inhibitor of Multidrug Resistance Proteins 1 and 2

  2003cited by this paper
• A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.

  2003cited by this paper
• Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.

  2003cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

  2003cited by this paper
• Mobilization of Ph chromosome‐negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate‐induced complete cytogenetic remission

  2003cited by this paper
• Letter to the Editorial Board

  2003cited by this paper
• A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

  2003cited by this paper
• ABC Transporters as Phenotypic Markers and Functional Regulators of Stem Cells

  2002cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

  2002cited by this paper
• Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

  2002cited by this paper
• Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

  2002cited by this paper
• Preferential induction of apoptosis for primary human leukemic stem cells

  2002cited by this paper
• Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia

  2002cited by this paper
• The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

  2001cited by this paper
• Stem cells, cancer, and cancer stem cells

  2001cited by this paper
• A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia

  2001cited by this paper
• Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

  2001cited by this paper
• Evolution of bone marrow transplantation--the original immunotherapy.

  2001cited by this paper
• Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice.

  2001cited by this paper
• The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells.

  2001cited by this paper
• Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.

  2001cited by this paper
• Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?

  2001cited by this paper
• A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia.

  2000cited by this paper
• Patient reports of complications of bone marrow transplantation

  2000cited by this paper
• Cell separation improves the sensitivity of detecting rare human normal and leukemic hematopoietic cells in vivo in NOD/SCID mice.

  2000cited by this paper
• Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells.

  2000cited by this paper
• Stem Cells Units of Development, Units of Regeneration, and Units in Evolution

  2000cited by this paper
• Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.

  1999cited by this paper
• Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

  1997cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Engraftment of bone marrow cells into normal unprepared hosts: effects of 5-fluorouracil and cell cycle status.

  1995cited by this paper
• Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.

  1994cited by this paper
• A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

  1994cited by this paper
• Characterization of CD34+HLA-DR-CD38+ and CD34+HLA-DR-CD38- progenitor cells from human umbilical cord blood.

  1994cited by this paper
• Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.

  1994cited by this paper
• Characterization of CD3 4+HLA-DR-CD38+ and CD34+HLA-DR-CD38-progenitor cells from human umbilical cord blood

  1994cited by this paper
• In vivo and in vitro characterization of long-term repopulating primitive hematopoietic cells isolated by sequential Hoechst 33342-rhodamine 123 FACS selection.

  1993cited by this paper
• Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization

  1990cited by this paper
• Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

  1990cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Stem cells in mammary gland differentiation and cancer

  1988cited by this paper
• Incidence of leukemia in atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950--71. Radiation dose, years after exposure, age at exposure, and type of leukemia.

  1978cited by this paper
• Complication of bone-marrow transplantation. Graft-versus-host disease resulting from chronic-myelogenous-leukaemia leucocyte transfusions.

  1970cited by this paper
• Persistent Mitosis of Transfused Homologous Leukocytes in Children Receiving Antileukemic Therapy

  1963cited by this paper
• Some speculations on the myeloproliferative syndromes.

  1951cited by this paper
• Editorial: Some Speculations on the Myeloproliferative Syndromes

  1951cited by this paper

• Taking a break: a therapeutic option for ECD?

  2025cites this paper
• Taxifolin promotes glioma stem cell differentiation via CYP1B1-mediated EMT suppression.

  2025cites this paper
• Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions

  2024cites this paper
• Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring

  2024cites this paper
• Extracellular Vesicles in Myeloid Neoplasms

  2022cites this paper
• Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

  2022cites this paper
• CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors

  2021cites this paper
• A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia

  2021cites this paper
• PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.

  2021cites this paper
• Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

  2020cites this paper
• Curcumin derivative C212 inhibits Hsp90 and eliminates both growing and quiescent leukemia cells in deep dormancy

  2020cites this paper
• KLF4 Represses DYRK2 Inhibition of Self-renewal and Survival Through c-Myc and p53 in Leukemia Stem/Progenitor Cells.

  2019cites this paper
• Curcumin Derivative C212 Inhibits Hsp90 and Eliminates Both Quiescent and Growing Leukemia Cells

  2019cites this paper
• DNA Damage Response in Quiescent Hematopoietic Stem Cells and Leukemia Stem Cells.

  2019cites this paper
• Xiao-AiPing inhibits proliferation and induces apoptosis of chronic myeloid leukemia cells through downregulating β-catenin signaling pathway

  2018cites this paper
• CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.

  2018cites this paper
• A Novel Mouse Model To Elucidate The Origins And Therapeutic Sensitivity Of Testicular Germ Cell Tumors

  2017cites this paper
• Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.

  2017cites this paper
• Isolation of colorectal cancer stem-like cells

  2016cites this paper
• The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias

  2016cites this paper
• Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

  2016cites this paper
• New Developments in Chronic Myeloid Leukemia: Implications for Therapy

  2016cites this paper
• Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells

  2015cites this paper
• Role of the microenvironment in maintenance and resistance of leukemic stem cells in Chronic Myelogenous Leukemia. BMP pathway and mechanical forces

  2015cites this paper
• Can we cure CML without transplantation

  2014cites this paper
• Kinase-inhibitor–insensitive cancer stem cells in chronic myeloid leukemia

  2014cites this paper
• imatinib in primary CML, but does not eliminate the quiescent fraction Dasatinib (BMS-354825) targets an earlier progenitor population than

  2013cites this paper
• Changing concepts of cancer stem cells and their application into targeted therapy for cancer

  2013cites this paper
• Small-molecule inhibition of BRD 4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia ( AML )

  2013influential citation
• provided by the niche and on BMPRIb overexpression Primitive CML cell expansion relies on abnormal levels of BMPs

  2013cites this paper
• The Bone Marrow Microenvironment as Niche Retreats for Hematopoietic and Leukemic Stem Cells

  2013cites this paper
• [Mechanisms of resistance to BCR-ABL kinase inhibitors].

  2013cites this paper
• Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression.

  2013cites this paper
• Combination of Imatinib with CXCR 4 antagonist BKT 140 overcomes the protective effect of stroma and targets CML in vitro and in vivo

  2013cites this paper
• DNA Repair Mechanisms in Other Cancer Stem Cell Models

  2013cites this paper
• Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

  2012cites this paper
• Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis

  2012cites this paper
• CD34+/CD38− stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin

  2012influential citation
• Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression.

  2012cites this paper
• Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

  2012influential citation
• Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability.

  2012cites this paper
• CD133-POSITIVE TUMORSTAMMZELLEN DER KOLONKARZINOMLINIE CT26 IN EINEM MAUSMODELL

  2012cites this paper
• Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts

  2012cites this paper
• BCR-ABL Tyrosine Kinase Sustained EVI 1 Expression in Chronic Myeloid Leukaemia

  2012cites this paper
• Genetic Mechanisms of Chronic Myeloid Leukemia Blastic Transformation

  2012cites this paper
• BCR‐ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia

  2012cites this paper
• Optimizing second-line therapy for chronic myeloid leukemia.

  2012cites this paper
• Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia

  2012cites this paper
• Mechanisms of resistance to BCR–ABL kinase inhibitors

  2011cites this paper
• The Stem Cell Niche: The Black Master of Cancer

  2011cites this paper
• DNA-damage response in tissue-specific and cancer stem cells.

  2011cites this paper
• Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy

  2011cites this paper
• Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

  2011cites this paper
• Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.

  2011cites this paper
• Leukemianet Recommendations from an expert panel on behalf of the European Evolving concepts in the management of chronic myeloid leukemia.

  2011cites this paper
• Mechanisms controlling hematopoietic stem cell functions during normal hematopoiesis and hematological malignancies

  2011cites this paper
• Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS.

  2011cites this paper
• Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept.

  2011cites this paper
• Therapeutic Strategies Targeting Cancer Stem Cells

  2011cites this paper
• Cancer stem cells and markers: New model of tumorigenesis with therapeutic implications

  2011cites this paper
• Tumor-targeting aptamers for the treatment of prostate cancer

  2011cites this paper
• Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia.

  2011cites this paper
• Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state

  2011cites this paper
• Brief report Deregulation of TWIST-1 in the CD34 (cid:1) compartment represents a novel prognostic factor in chronic myeloid leukemia

  2011cites this paper
• Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells

  2011cites this paper
• Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop

  2011cites this paper
• Identification of CD133−/Telomeraselow Progenitor Cells in Glioblastoma-Derived Cancer Stem Cell Lines

  2011cites this paper
• Targeting aurora kinases in cancer treatment.

  2011cites this paper
• Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.

  2011cites this paper
• The characterization of the role of myeloid translocation gene 16 in hematopoietic progenitor and stem cell functions

  2011cites this paper
• prognostic factor in chronic myeloid leukemia compartment represents a novel + Deregulation of TWIST-1 in the CD34

  2011cites this paper
• Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target

  2011cites this paper
• The Bcr-Abl kinase regulates the actin cytoskeleton via a GADS/Slp-76/Nck1 adaptor protein pathway.

  2010cites this paper
• Understanding the cancer stem cell

  2010cites this paper
• The Hemopoietic Stem Cell Niche Versus the Microenvironment of the Multiple Myeloma-Tumor Initiating Cell

  2010cites this paper
• The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?

  2010cites this paper
• Normal stem cells and cancer stem cells: similar and different.

  2010cites this paper
• Osteoclasts are involved in the maintenance of dormant leukemic cells.

  2010cites this paper
• Chronic myeloid leukemia: mechanisms of blastic transformation.

  2010cites this paper
• Irrespective of CD34 expression, lineage‐committed cell fraction reconstitutes and re‐establishes transformed Philadelphia chromosome‐positive leukemia in NOD / SCID / IL‐2Rγc−/− mice

  2010cites this paper
• Chronic Myeloid Leukemia: Pathophysiology and Therapeutics

  2010cites this paper
• The elusive CML stem cell: does it matter and how do we eliminate it?

  2010cites this paper
• Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia

  2009cites this paper
• Thyrosin kinase inhibitors: nilotinib

  2009cites this paper
• Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.

  2009cites this paper
• [Immunological evaluation for CML and its possibility for an immunotherapy].

  2009cites this paper
• Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.

  2009cites this paper
• The Stem State in Cancer

  2009cites this paper
• CML: a model for targeted therapy.

  2009cites this paper
• Interferon in chronic myeloid leukaemia: past and future.

  2009cites this paper
• Imatinib resistance in CML.

  2009cites this paper
• Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes.

  2009cites this paper
• Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents.

  2009cites this paper
• Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

  2009cites this paper
• IFN-α wakes up sleeping hematopoietic stem cells

  2009cites this paper
• Cancer stem cells: the emerging challenge of drug targeting.

  2009cites this paper
• Advancing CML Patient Care : Closing in on a Cure?

  2009cites this paper
• The role of GATA-1 isoforms in haematopoiesis

  2009cites this paper
• Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells

  2009cites this paper
• Cancer stem cells and impaired apoptosis.

  2008cites this paper